TUCSON, Ariz., May 25, 2026 (GLOBE NEWSWIRE) — Umbrella Labs today issued a company announcement confirming an internal documentation and traceability update for epitalon peptide reference material, provided strictly for laboratory developmental research use only. This update is part of Umbrella Labs’ ongoing standardization initiative focused on identity-field consistency, record continuity, and reproducibility support for laboratories that rely on peptide inputs across multi-run bench workflows.
Effective immediately, the epitalon update aligns internal records and outward-facing reference language under a single, consistent documentation framework designed to reduce ambiguity in receiving logs, internal procurement paperwork, and study documentation. This announcement is limited to operational and documentation changes intended to support clean recordkeeping and repeatable laboratory workflows, and it does not introduce clinical, diagnostic, therapeutic, or human-use positioning.
Umbrella Labs is issuing this update in response to evolving press release acceptance requirements that prioritize company announcements and operational updates, particularly where research-only materials can otherwise be misclassified as health-related content. The purpose of this release is to document a specific company change in how epitalon is named, recorded, and traced for research procurement and laboratory documentation, with a clear emphasis on traceability, internal controls, and research-only scope…